Related Experiment Video
Updated: Jun 9, 2026
Robot-Assisted Radical Antegrade Modular Pancreatosplenectomy Including Resection and Reconstruction of the Spleno-Mesenteric Junction
Published on: January 3, 2020
Prognostic Significance of Achieving the Radical Cystectomy-Pentafecta After Neoadjuvant Chemotherapy and
Kyotaro Fukuta1, Yutaro Sasaki2, Kei Daizumoto2
1Department of Urology, Tokushima Prefectural Central Hospital, Tokushima, Japan.
Objective:
This collaborative, multi-institutional retrospective study aimed to evaluate whether achieving the radical cystectomy-pentafecta contributes to improved outcomes in patients with muscle-invasive bladder cancer undergoing neoadjuvant chemotherapy followed by robot-assisted radical cystectomy.
Methods:
We retrospectively analyzed 195 patients with muscle-invasive bladder cancer who underwent robot-assisted radical cystectomy with intracorporeal urinary diversion at four affiliated institutions. All had a minimum follow-up of 12 months. According to previously established criteria, patients who simultaneously demonstrated (i) negative soft tissue surgical margins, (ii) ≥ 16 lymph node yield, (iii) absence of major complications at 90 days, (iv) absence of urinary diversion-related long-term sequelae, and (v) absence of clinical recurrence in the first year were considered to have achieved the radical cystectomy-pentafecta.
Results:
The overall radical cystectomy-pentafecta achievement rate was 46.2% (46.5% in the neoadjuvant chemotherapy group and 45.3% in the no chemotherapy group). In the neoadjuvant chemotherapy group, patients who achieved the radical cystectomy-pentafecta demonstrated significantly better overall survival (p = 0.038), cancer-specific survival (p = 0.009), and recurrence-free survival (p < 0.001) than those who did not.
Conclusions:
The radical cystectomy-pentafecta is a valuable tool to assess the quality of robot-assisted radical cystectomy with intracorporeal urinary diversion. Its achievement may be associated with improved outcomes in patients with muscle-invasive bladder cancer undergoing neoadjuvant chemotherapy prior to surgery.
